Drugs /
onvansertib
Overview
Clinical Trials
Onvansertib has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating onvansertib, 2 are phase 1/phase 2 (2 open) and 2 are phase 2 (2 open).
Deficient DNA Mismatch Repair (dMMR), KRAS Exon 2 Mutation, and KRAS Exon 3 Mutation are the most frequent biomarker inclusion criteria for onvansertib clinical trials.
Colorectal carcinoma, pancreatic ductal adenocarcinoma, and prostate adenocarcinoma are the most common diseases being investigated in onvansertib clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.